Innocan Pharma Corp
Change company Symbol lookup
Select an option...
INNPF Innocan Pharma Corp
PNI PIMCO New York Municipal Income Fund II
NIB iPath? Bloomberg Cocoa Subindex Total Return(SM) ETN
DG Dollar General Corp
SPCO Stephan Co
KEX Kirby Corp
GM General Motors Co
F Ford Motor Co
MSFT Microsoft Corp
TWTR Twitter Inc
Go


Based in Israel
Company profile

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

Closing Price
$0.3731
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.3731
Day's Low
0.3731
Volume
(Heavy Day)
Volume:
200

10-day average volume:
200
200

Display:

Providers:

UpdateCancel
6 providers
August 11, 2022
Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following...(Newsfile)

August 05, 2022
Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled...(Newsfile)

July 29, 2022
Innocan Pharma Files PCT Patent Application for Diabetic Symptoms

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled...(Newsfile)

July 12, 2022
Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 12, 2022) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has appointed Nissim Vasilevski as Analytical...(Newsfile)

July 06, 2022
Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive results in a preclinical trial involving a dog...(Newsfile)

June 24, 2022
Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 24, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful preclinical trials in dogs with osteoarthritis...(Newsfile)

June 17, 2022
Innocan Pharma Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new PCT patent application entitled...(Newsfile)

June 10, 2022
Innocan Reports Successful Preliminary Trial Results Regarding Epilepsy in Dogs

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 10, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the successful preliminary results of a small-scale...(Newsfile)

May 30, 2022
Innocan Pharma Announces Q1 2022 Results with 215% Increase in Cash Balance and 200% Increase in Working Capital

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 30, 2022) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to report its financial results for the quarter ended March 31, 2022.(Newsfile)

May 17, 2022
Innocan Pharma Obtains Receipt for Final Base Shelf Prospectus

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed and obtained a receipt for a final short...(Newsfile)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.